There are 2789 resources available
939P - Phase II study of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC)
Presenter: David Hsiehchen
Session: ePoster Display
940P - Dose-escalation trial of OBP-301, novel telomerase-specific oncolytic virus in advanced hepatocellular carcinoma
Presenter: Jeong Heo
Session: ePoster Display
941P - Neoadjuvant radiotherapy improves overall survival in patients with resectable hepatocellular carcinomas
Presenter: Zhiwen Luo
Session: ePoster Display
Resources:
Abstract
942P - The role of intraoperative electron radiotherapy in centrally located hepatocellular carcinomas treated with narrow-margin (<1 cm) hepatectomy: A prospective, phase II study
Presenter: Liming Wang
Session: ePoster Display
Resources:
Abstract
943P - Long-term outcome of the oldest-old patients (85 years or older) underwent proton beam therapy for hepatocellular carcinoma
Presenter: Takashi Iizumi
Session: ePoster Display
944P - Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC II and III stage: A single-center prospective phase II trial
Presenter: Xinrong Yang
Session: ePoster Display
946P - Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C: A prospective, single-arm, phase II trial (TRIPLET study)
Presenter: Tian-Qi Zhang
Session: ePoster Display
947P - Updated survival and secondary safety and efficacy analyses from CA 209-678: A phase II open-label single-centre study of Y90-radioembolisation (Y90) in combination with nivolumab in Asian patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Joycelyn Lee
Session: ePoster Display
948P - Predicting the efficacy of lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC) using radiomics features of tumors extracted from baseline MRI
Presenter: Huichuan Sun
Session: ePoster Display